Chiesi gets ex-US rights to Protalix's Phase III Fabry candidate; deal expanded to include US rights
Protalix BioTherapeutics Inc. licensed Chiesi Farmaceutici SPA exclusive rights to develop and commercialize its Phase III PRX102 (pegunigalsidase alfa) for Fabry disease in all territories except the US where Protalix retains rights.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com